制药提价与抑制仿制药方式 472条(本栏目收费,不能显示细节,电话13136136841)
threat of to pharma executives, 7 7
generic delay. See also citizen petitions as delay 0
tactic; Generation 2.0 strategies; Generation 0
no- authorized- generic agreements, 61,64 64
Noerr- Pennington cases, 99,100, 134 134
non- patent exclusivities, 32 32
NPR’s All Things Considered, 94 94
Obama, Barack on rising costs of prescription medication, 5 5
off- label use of medication, 104 104
Opana (opiate painkiller, Edon), 94,95 95
Orange book, 29,30, 55 55
Orphan Drug Act, 33, 109 109
Orphan Drug Designation 0
for Abilify (antipsychotic, Otsuka), 110,112 112
for Crestor (statin, AstraZeneca),108,110, 111,112 112
Paragraph IV certification, 22. See also Hatch- Waxman Act (U.S., 1984)defined, 29 29
duopoly and profits created by exclusivity period, 22, 30,31 31
exclusivity period elapsement for first generic filers and, 38 38
K- Dur case, 50,51, 52 52
patent infringement litigation and, 22 22
weak or misapplied patents for quick generic entry and, 29,30 30
allowance of patent- protected brand- name information for generic research via Hatch- Waxman Act, 26,27 27
business method patents, 84 84
costs to society of abuse of patent systems and, 23 23
method- of- use patents, 103 103
new drugs non- patent exclusivities in, 32,33 33